drugset
drugset / Trial / NCT05812404

Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects

NCT05812404 ↗

Phase 1 Unknown 36 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open-label, three-period, three-sequence, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacokinetics of DWC202201 after co-administration of DWP14012 and DWC202201 in healthy subjects

Timeline

Start
2022-10-26
Primary completion
2023-03-28
Completion
2023-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule 40 mg —
Subject DWC202201 Unknown 40 mg —

Indications

No indication recorded.